Company demonstrated significant clinical progress across multiple product lines with strong efficacy data (94.2% remapping success rate, 100% acute electrical isolation), received FDA breakthrough designation, expanded patient enrollment, and maintained strong cash position of $119.3 million. However, operating losses increased and cash burn accelerated, which tempers the outlook despite clinical achievements.
Also mentions PLSE
Articles that tag PLSE but are mainly about other companies.
None recently.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
